Please assess the completion status of the following clinical trial:

Trial Title: Oxaliplatin in Treating Women With Advanced or Metastatic Breast Cancer That Has Not Responded to Previous Chemotherapy

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed advanced or metastatic breast cancer~* Bidimensionally measurable disease~  * At least one lesion at least 2 cm in one dimension by CT scan or MRI~* Must have failed prior anthracycline/taxane based chemotherapy as defined by one of the following:~  * Stage IV disease treated with anthracycline/taxane combination as first line therapy for advanced or metastatic disease~ * Stage IV disease treated with first line anthracycline therapy and second line taxane therapy for advanced or metastatic disease~ * Any adjuvant treatment other than anthracycline based therapy followed by anthracycline/taxane combination as first line therapy for advanced or metastatic disease~ * Any adjuvant therapy other than anthracycline based therapy followed by first line anthracycline based therapy and second line taxane based therapy for advanced or metastatic disease~ * Adjuvant anthracycline based therapy followed by relapse after 6 months treated with anthracycline/taxane combination as first line therapy or first line anthracycline based therapy and second line taxane based therapy for advanced or metastatic disease~ * Adjuvant anthracycline based therapy followed by relapse within 6 months treated with first line taxane based therapy for advanced or metastatic disease~* Disease progression within 6 months of last taxane based chemotherapy~* No brain metastases~* Hormonal receptor status:~  * Not specified~PATIENT CHARACTERISTICS:~Age:~* 18 and over~Sex:~* Female~Menopausal status:~* Not specified~Performance status:~* WHO 0-2~Life expectancy:~* At least 3 months~Hematopoietic:~* Absolute neutrophil count greater than 2,000/mm\^3~* Platelet count greater than 100,000/mm\^3~Hepatic:~* Bilirubin less than 1.5 times upper limit of normal (ULN)~* Alkaline phosphatase and transaminases no greater than 2.5 times ULN (no greater than 5 times ULN in case of liver metastases)~Renal:~* Creatinine less than 1.25 times ULN~Cardiovascular:~* LVEF at least 50% if prior total dose of doxorubicin 550 mg/m2 or greater, epirubicin 900 mg/m2 or greater, or pirarubicin 700 mg/m2 or greater~* No prior or active congestive heart failure, myocardial infarction, or angina~* No uncontrolled hypertension or arrhythmia~Other:~* No unstable systemic disease~* No active infection~* No grade 2 or greater peripheral neuropathy~* No psychological, familial, sociological, or geographical condition that would preclude study~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* No prior high dose chemotherapy with hematopoietic rescue~* No concurrent immunotherapy~* No concurrent filgrastim (G-CSF) or sargramostim (GM-CSF) for prevention of neutropenia~Chemotherapy:~* See Disease Characteristics~* At least 4 weeks since prior chemotherapy~* At least 1 prior taxane based chemotherapy for advanced or metastatic disease~* No prior high dose chemotherapy with hematopoietic rescue~* No prior platinum based chemotherapy~* No prior taxane chemotherapy other than docetaxel or paclitaxel~* No prior adjuvant or neoadjuvant therapy with taxane/anthracycline based combination chemotherapy~Endocrine therapy:~* No concurrent steroids except in case of allergy prevention, emesis prophylaxis, or long term treatment for more than 3 months prior to study~* No concurrent hormonal anticancer therapy~Radiotherapy:~* No prior radiotherapy to study site unless evidence of disease progression~* Concurrent local radiotherapy allowed for pain relief~Surgery:~* At least 4 weeks since prior major surgery~Other:~* At least 4 weeks since prior anticancer and/or investigational drug~* No concurrent bisphosphonates unless started at least 2 months prior to study~* No other concurrent anticancer therapy~* No other concurrent experimental drugs

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues